Skip to content
Screener

Halozyme Therapeutics HALO Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
$89.9M+27.7%
AMP
Amphastar PharmaceuticalsAMPH
$29.44M+5.9%
AptarGroup logo
AptarGroupATR
$37.5M—
Opko Health logo
Opko HealthOPK
$17M-38.9%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$41.46M+26.1%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$6.05M+173%

Other financials

Income statement

See full
Revenue$481.0M+47.7%
Gross profit$401.8M+43.8%
Operating income$287.7M+42.1%
Net income$229.9M+39.2%
EPS (diluted)$1.90+42.9%

Balance sheet

See full
Cash & equivalents$164.0M+165%
Total debt$2.2B+41.6%
Total equity$143.5M-56.9%
Total assets$2.6B+25.5%

Cash flow

See full
Operating cash flow$240.9M+142%
CapEx$4.2M+167%
Free cash flow$236.7M+141%

Valuation

See full
Market cap$10.17B+39.6%
Enterprise value$12.19B+39.0%
P/E14.1×-4.1×
P/S6.1×-0.1×

Profitability

See full
Gross margin82.4%-1.8pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin48.5%+2.6pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity15.2×+10.6×
Current ratio2.7×-5.7×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001159036-26-000104

FAQ

What is Halozyme Therapeutics's other non-current liabilities?
Halozyme Therapeutics (HALO) reported other non-current liabilities of $102.68M in Q2 2026.
How has Halozyme Therapeutics's other non-current liabilities changed year-over-year?
Halozyme Therapeutics's other non-current liabilities increased by 32.0% year-over-year, from $77.77M to $102.68M.
What is the long-term trend for Halozyme Therapeutics's other non-current liabilities?
Over 5 years (2020 to 2025), Halozyme Therapeutics's other non-current liabilities has grown at a 101.1% compound annual growth rate (CAGR), from $3.47M to $113.86M.
What does other non-current liabilities mean?
Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.

Ask your AI about Halozyme Therapeutics's other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude